肖恩地希区柯克
- 关于
- 教育
- 奖励和荣誉
- 研究
传记
去韦恩州立大学化学学士(1990年)。就读于加州大学戴维斯分校的博士(1995)。完成了博士后研究在威斯康辛大学麦迪逊。
当前的课程
220年措施基础有机化学
299年.010独立的荣誉在化学学习
499年.010独立研究的硕士论文
290年.010化学的研究
490年.010化学的研究
380年措施化学结构测定
499年04独立研究的硕士论文
490年.008化学的研究
教学的兴趣和领域
我对有机化学教学的兴趣。我教二年级的课程有机化学,有机化学研究生,在碳碳键形成反应和立体化学专题。格瓦拉230:提供的课程是作为第一个在为期一年的开销序列研究有机化学。本课程是建立一个坚实的基础有机化学对学生科学的职业准备在化工、学术界、医学、药学或其他健康相关的领域。类建立了基础的讲座,互动课堂参与、视频演示和示威,专注于有机化学的艺术和科学。格瓦拉232:格瓦拉232作为最后的课程是一个双向的有机化学序列和专业要求。类构建基础之上,介绍了新概念直接相关的生物学和生物化学。这些元素通常带来大学生的利益,因为它是一个跨学科的重点。切380.51:切380.51是一个课程,旨在满足研究生和本科生的需求。类是一个过渡课程,帮助本科生和研究生加强基础知识在大学二年级期间学到的。 I have always believed that the establishment of the fundaments is critical. The examples that are drawn from in class are taken from the immediate chemical literature. CHE 426: CHE 426 is a class meant to help undergraduate and M.S. graduate students gain of strong understanding of organic chemistry beyond the undergraduate experience. The class covers a number of subjects that are important in contemporary organic synthesis. Many graduate students often tell me that CHE 426 was one of their best classes that they have taken during their graduate career.
研究方向和领域
我的研究兴趣领域的分子的不对称性。随着我们进入21世纪,社会变化和发展的需要。制药行业正在发生变化。新兴挑战制药提起涉及许多不同的方面。这些方面之一是分子手性,某些分子的能力作为右撇子和左撇子版本存在。目前手性药物的全球销售超过每年1500亿美元。许多这些药用制剂被选择性地准备为“右撇子”的形式或“左撇子”的形式,因为他们可以表现出不同的生物效应。我的研究都集中在发展中各种方法的单一对映体的选择性制备材料。2004年,石油研究基金的资助(由ACS)允许我使用各种各样的研究生和本科生在发展中一个类的化学试剂诱导手性材料的选择性形成的能力。相关的成功和挑战oxadiazinones导致出现新的研究项目集中在不对称催化剂的使用。 The catalysis work led to the establishment of a patent for a method that was developed for the Ephedra alkaloid known as pseudonorephedrine. This work was primarily led by Jonathan Groeper. Before this patent work, pseudonorephedrine was commercially available for nearly $16,800 per gram. This work makes the cost of the material about $20 per gram. Sigma-Alrich also saw the value of his compound and has recently developed irs own synthetic procedure to make this material available. We also developed several new classes of chiral catalysts called oxazolidines, oxadiazines and beta-hydroxysalicylhydrazones. These catalysts have shown promise in the application in trials of the asymmetric 1,2-addition of diethylzinc to aromatic and aliphatic aldehydes. This pilot work led to my research group successfully securing a grant from the National Science Foundation in 2007 for $226,050. This grant is being used to increase the diversity of chemical methods that my research group employs in the search for methods of the very selective formation of chiral molecules. Working with a lead graduate student, Raleigh Parrott, an undergraduate student Seshanand Chandrashekar, and high school student Brittany Morgan, we have just published our results of an effective tridentate catalyst in the journal Tetrahedron: Asymmetry. We have developed several families of ligands that already show much promise in terms of their use in reactions such as the asymmetric allylic alkylation reactions. One of our current targets that we are nearing completion on is the medicinal agent leveteracitam, a clinically effective treatment for epilepsy. In addition to this work, we have developed several families of ligands that already show much promise in terms of their use in reactions such as the asymmetric allylic alkylation reactions. In conjunction with my research activities, I am constantly developing my mentoring activities with my research students. The activities include weekly meetings where students learn about finding, applying for, and securing positions in the chemical industry. Students who have worked with me in carrying out studies on chiral materials are employed around the country at companies such as Alcon Laboratories (Texas), Amgen (California), Anderson & Associates (Illinois), DeCode Laboratories (Illinois), GlaxoSmithKline (Pennsylvania). Jonathan Groeper, a 2007 graduate is now employed at Merck Research Laboratories (New Jersey) and Raleigh Parrott II, another 2007 graduate is working with the Federal Bureau of Investigation (Virginia).